Sangui Biotech International Inc. Reports Preliminary Unaudited Revenue Results for the First Half Ended Dec. 31, 2016
January 12, 2017 at 04:50 am EST
Share
Sangui BioTech International Inc. reported preliminary unaudited revenue results for the first half ended Dec. 31, 2016. The company reported revenues of USD 36,000 from license fees in the first half year of fiscal 2017 (as of December 31, 2016). Due to increased revenues of the wound spray Granulox, the resulting licensing income in the first half year increased by 33% compared to the same period of the previous year. After a cautious first quarter, especially a strong end-of-year business was responsible for this development.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
